Alpha-Synuclein Targeting Monoclonal Antibody Therapy Treatment for Parkinson’s Disease
DOI:
https://doi.org/10.47611/jsrhs.v13i2.6825Keywords:
Neuroscience, Alpha-Synuclein, Antibody, Monoclonal Antibody, Therapy, Treatment, Parkinson's, Parkinson's Disease, Alzheimer's, Alzheimer's Disease, Brain, Lewy Bodies, Lewy Body, Disease, Neurobiology, Anatomy, Prasinezumab, Cinpanemab, PD01A (AFFITOPE), UB-312 Vaxxinity, Shoni Jain, Shoni, Westview High School, ImmunotherapyAbstract
An investigation was done on plausible antibody treatments for alpha-synuclein, which is an instigator for the dopamine-lacking neurodegenerative disease Parkinson’s to occur in patients due to its aggregation. Trials working towards slowing the pathogenesis of Parkinson’s Disease through monoclonal antibodies for alpha-synuclein were analyzed. Previously, similar therapies were done in other neurodegenerative diseases like Alzheimer’s, allowing for a hopeful hypothesis in Parkinson’s. Active and Passive antibody treatments were compared and discussed: Pranizeumab, Cipanemab, PD01A, and UB-312. Trials often found success in animal models and not the same outcome in humans within the passive studies. In active studies, however, more hopeful results were presented, showing built immunity towards alpha-synuclein and enhancement of motor symptoms. Though some studies led to a dead end, studies use information to complete future phases. Monoclonal antibody treatment for Parkinson’s Disease is a real future in the fight for reducing the pathogenesis of Parkinson’s Disease.
Downloads
References or Bibliography
(n.d.). ClinicalTrials.gov: Home. Retrieved February 29, 2024, from https://www.clinicaltrials.gov/
ACI-7104.056 | ALZFORUM. (2024, February 5). Alzforum. Retrieved February 29, 2024, from https://www.alzforum.org/therapeutics/affitope-pd01a-pd03a
AC Immune's Robust Pipeline focused on neurodegenerative diseases. (n.d.). AC Immune SA. Retrieved February 29, 2024, from https://www.acimmune.com/pipeline/
Active Immunotherapy and Passive Immunotherapy. (n.d.). Beckman Coulter. Retrieved February 29, 2024, from https://www.beckman.com/support/faq/research/active-immunotherapy-and-passive-immunotherapy
Alpha Synuclein – The Science of Parkinson's. (n.d.). The Science of Parkinson's. Retrieved February 29, 2024, from https://scienceofparkinsons.com/alpha-synuclein/
Alzheimer's disease - Symptoms and causes. (n.d.). Mayo Clinic. Retrieved February 29, 2024, from https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
Anti-amyloid Oligomer Monoclonal Antibodies for Treatment of Parkinson's Disease | Parkinson's Disease. (n.d.). The Michael J. Fox Foundation for Parkinson's Research. Retrieved February 29, 2024, from https://www.michaeljfox.org/grant/anti-amyloid-oligomer-monoclonal-antibodies-treatment-parkinsons-disease
Aron, L. (n.d.). Figure 2. Loss of substantia nigra (SN) neurons causes Parkinson's... ResearchGate. Retrieved February 29, 2024, from https://www.researchgate.net/figure/Loss-of-substantia-nigra-SN-neurons-causes-Parkinsons-disease-Pathological_fig1_45314202
Ciccone, I. (2023, August 1). UB-312 Displays Target Engagement of Toxic Alpha-Synuclein in Phase 1 Trial for Parkinson Disease. NeurologyLive. Retrieved February 29, 2024, from https://www.neurologylive.com/view/ub-312-displays-target-engagement-toxic-alpha-synuclein-phase-1-trial-parkinson-disease
Cummings, J. (2023, April 15). Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics. NCBI. Retrieved February 29, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195708/
Jamal, F. (n.d.). Immunotherapies Targeting α-Synuclein in Parkinson Disease. NCBI. Retrieved February 29, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473734/
Kharel, S. (2022, November 17). Future of Monoclonal Antibody Therapy in Parkinson's Disease. NCBI. Retrieved February 29, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259150/
Lewy Body Dementia (LBD). (n.d.). Johns Hopkins Medicine. Retrieved February 29, 2024, from https://www.hopkinsmedicine.org/health/conditions-and-diseases/dementia/dementia-with-lewy-bodies
Lewy Body Dementias | Memory and Aging Center. (n.d.). UCSF Memory and Aging Center. Retrieved February 29, 2024, from https://memory.ucsf.edu/dementia/parkinsons/lewy-body-dementias
Monoclonal Antibodies: Definition & How Treatment Works. (2021, November 16). Cleveland Clinic. Retrieved February 29, 2024, from https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies
Monoclonal antibody drugs for cancer: How they work. (n.d.). Mayo Clinic. Retrieved February 29, 2024, from https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808
Okun, M. (2022, August 16). Take home lessons from the failures of the two Parkinson's monoclonal antibody studies — Parkinson Secrets. Parkinson Secrets. Retrieved February 29, 2024, from https://www.parkinsonsecrets.com/blog/take-home-lessons-from-the-failures-of-the-two-parkinsons-monoclonal-antibody-studies
Parkinson's disease - Causes. (n.d.). NHS. Retrieved February 29, 2024, from https://www.nhs.uk/conditions/parkinsons-disease/causes/
Parkinson's disease - Symptoms and causes. (2023, May 26). Mayo Clinic. Retrieved February 29, 2024, from https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. (n.d.). PubMed. Retrieved February 29, 2024, from https://pubmed.ncbi.nlm.nih.gov/32562684/
Stefanis, L. (n.d.). α-Synuclein in Parkinson's Disease - PMC. NCBI. Retrieved February 29, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281589/
Surtini, R. (2021, May 6). ,. , - YouTube. Retrieved February 29, 2024, from https://www.nejm.org/doi/full/10.1056/NEJMoa2202867
Surtini, R. (2021, May 6). ,. , - YouTube. Retrieved February 29, 2024, from https://www.nejm.org/doi/full/10.1056/NEJMoa2203395
Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson's disease. (n.d.). Open Exploration. Retrieved February 29, 2024, from https://www.explorationpub.com/Journals/ent/Article/100448
UB-312 | ALZFORUM. (2023, May 10). Alzforum. Retrieved February 29, 2024, from https://www.alzforum.org/therapeutics/ub-312
What Happens to the Brain in Alzheimer's Disease? (2024, January 19). National Institute on Aging. Retrieved February 29, 2024, from https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease
What is Alzheimer's Disease? Symptoms & Causes | alz.org. (n.d.). Alzheimer's Association. Retrieved February 29, 2024, from https://www.alz.org/alzheimers-dementia/what-is-alzheimers
What is anti-amyloid therapy for Alzheimer's disease? (2023, May 12). Nebraska Medicine. Retrieved February 29, 2024, from https://www.nebraskamed.com/neurological-care/health/conditions-and-services/what-is-anti-amyloid-therapy-for-alzheimers-disease
What Is Lewy Body Dementia? Causes, Symptoms, and Treatments. (2021, July 29). National Institute on Aging. Retrieved February 29, 2024, from https://www.nia.nih.gov/health/lewy-body-dementia/what-lewy-body-dementia-causes-symptoms-and-treatments
What is Parkinson's? (n.d.). Parkinson's Foundation. Retrieved February 29, 2024, from https://www.parkinson.org/understanding-parkinsons/what-is-parkinsons
Young-Onset Parkinson's Disease. (n.d.). Johns Hopkins Medicine. Retrieved February 29, 2024, from https://www.hopkinsmedicine.org/health/conditions-and-diseases/parkinsons-disease/youngonset-parkinsons-disease
Published
How to Cite
Issue
Section
Copyright (c) 2024 Shoni Jain; Dr. Jobin Varkey, Virgel Torremocha, Jothsna Kethar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
